• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • 0 CME Hours
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
#Grand Rounds

Uterine Artery Embolization or MRI-guided Focused Ultrasound for Uterine Leiomyoma Treatment?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE: 

  • Laughlin-Tommaso et al. (AJOG, 2019) compared uterine artery embolization vs MRI-guided focused ultrasound surgery for the treatment of fibroids

METHODS: 

  • Randomized controlled trial (RCT) 
    • Fibroid Interventions: Reducing Symptoms Today and Tomorrow study (FIRSTT) study  
    • Women who declined to be randomized were also followed as a observational cohort group  
    • Premenopausal women  
    • Symptomatic uterine fibroids 
  • Women either received 
    • Uterine artery embolization 
    • MRI-guided focused ultrasound surgery 
  • Primary outcome: Re-intervention for fibroids within 36 months 
  • Secondary outcomes  
    • Change in serum AMH levels to assess ovarian function | Fibroid symptoms | Quality of life | Pain | Sexual function 
  • Results analyzed using a comprehensive cohort design

RESULTS: 

  • 83 women (mean age, 44.4 years) were treated and analyzed using the comprehensive cohort design  
    • 43 in the magnetic resonance imaging–guided focused ultrasound surgery group  
      • 27 randomized 
    • 40 in the uterine artery embolization group  
      • 22 randomized 
  • Baseline characteristics the same between treatment groups, except for higher fibroid load in the uterine artery embolization arm 
  • The MRI ultrasound group had a higher risk of reintervention  
    • Hazard ratio (HR) 2.81 (95% CI, 1.01–7.79) 
  • Uterine artery embolization showed a significantly greater absolute decrease in AMH levels at 24 months compared with MRI ultrasound group (P=0.03) 
  • While quality of life and pain scores improved in both arms, uterine artery embolization arm showed greater benefit (P≤0.006)  
    • Differences persisted even after adjusting for baseline quality of life and pain scores  
  • Higher pretreatment AMH level and younger age at treatment increased the overall risk of reintervention

CONCLUSION: 

  • Authors acknowledge a limitation of this study is that they did not meet their desired sample size and many women preferred to be in an observational cohort rather than be randomized  
  • Uterine artery embolization led to lower uterine leiomyoma associated re-intervention rates and greater improvement in symptoms, compared to MRI-guided ultrasound  
  • AMH was a predictor of outcome and authors suggest that impairment of ovarian reserve may mediate fibroid treatment  
    • More robust ovarian reserve may mitigate the treatment effect  
  • Authors also point out that since the study’s completion, there is newer technology available for MRI-guided ultrasound surgery and reintervention rates may be more comparable to uterine artery embolization

Learn More – Primary Sources: 

FIRSTT study: randomized controlled trial of uterine artery embolization vs focused ultrasound surgery

Now You Can Get ObG Clinical Research Summaries Direct to Your Phone

Learn More »

image_pdfFavoriteLoadingFavorite

< Previous
All #Grand Rounds Posts
Next >

Related ObG Topics:

Uterine Artery Embolization or Focused Ultrasound for Uterine Fibroids?
Uterine Artery Embolization or Hysterectomy for Fibroids?
What Uterine-Sparing Treatment for Fibroids Has the Best Outcomes?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • #Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

ObG Library

  • Hysteroscopy
  • Fertility
  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Log In to ObG First

Please log in to access OBGFirst and the 2T Ultrasound Atlas

Password Trouble?

Sign Up for ObGFirst

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!

ObG First Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site